Argá Medtech Initiates First-in-Human Trial to Assess the Safety and Effectiveness of Coherent Sine Wave Electroporation in Patients with Atrial Fibrillation
EPALINGES, Switzerland, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Arg Medtech announced today that it has begun enrollment in their First-in-Human Clinical Trial Coherent Sine Burst Electroporation (CSE) System Pilot Study in Patients with Atrial Fibrillation (BURST-AF).
- EPALINGES, Switzerland, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Arg Medtech announced today that it has begun enrollment in their First-in-Human Clinical Trial Coherent Sine Burst Electroporation (CSE) System Pilot Study in Patients with Atrial Fibrillation (BURST-AF).
- The study is designed to test the acute safety and efficiency of the Arg Medtech CSE Ablation System in the treatment of atrial fibrillation (AFib).
- The CSE system consists of a configurable (circular, linear, and focal) ablation catheter and pulsed field ablation (PFA) generator.
- In contrast to all other PFA waveforms, CSE employs a unique sinusoidal wave instead of a square wave.